WebApr 10, 2024 · OPT-302: Opthea Limited OPT-302 is a first-in-class VEGF-C/D inhibitor. It is a soluble fusion protein comprising immunoglobulin-like domains 1 to 3 of the extracellular domain of vascular endothelial growth factor receptor 3 (VEGFR-3) fused to the Fc fragment of human immunoglobulin G1 (IgG1) (Opthea, 2024). WebOct 28, 2024 · Opthea Limited (OPT) develops and commercialise therapies primarily for eye disease. Opthea's lead asset, OPT -302, is a soluble form of VEGFR-3 in clinical development as a novel therapy for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The Group operates in one industry and one geographical area, …
Top broker tips Opthea shares as a strong buy during the …
WebFeb 24, 2024 · Opthea ( ASX:OPT) First Half 2024 Results Key Financial Results Net loss: US$77.1m (loss widened by 104% from 1H 2024). US$0.17 loss per share (further … WebSep 9, 2024 · Stockbroker Bell Potter’s Tanushree Jain reckons $4.44 is a fair estimate of the value of Opthea shares, taking into account what industry majors have paid for other biotech juniors working up potentially valuable ideas in the same field. In mid-August she hiked her value of Opthea shares from $2.79 earlier. pompano beach house for sale
Investor Information - Opthea
WebIn depth view into OPT (Opthea) stock including the latest price, news, dividend history, earnings information and financials. ... Percent of Shares Outstanding Short: Upgrade: Jul … WebShare Price Presentations Corporate Governance Investor Information Shareholder Meetings Our next AGM Opthea’s Annual General Meeting will take place virtually on Wednesday 16 … WebJun 10, 2024 · Impressively, the Opthea share price has skyrocketed more than 350% compared to this time last year. Opthea is a developer of novel biologic therapies for the treatment of eye diseases. The company specialises in the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). pompano beach in what county